BioNTech CEO Ugur Sahin Sells $5.95M in Shares Under Pre-Arranged 10b5-1 Plan

Executive Summary

On October 9, 2026, BioNTech SE (BNTX) Chief Executive Officer and 10% owner Ugur Sahin reported the sale of 63,209 Ordinary Shares across October 8 and October 9, 2026, generating gross proceeds of approximately $5.95 million.

Transaction Breakdown

• October 8, 2026: Sold 27,000 shares at a weighted average price of $92.3142 ($2,492,483.40 total).
• October 9, 2026: Sold 36,209 shares at a weighted average price of $95.3733 ($3,453,371.72 total).
• Blended Average Price: ~$94.07 per share.

Holdings Analysis

• Direct Ownership: Post-transaction direct holdings decreased from 63,209 shares to 0.
• Indirect Ownership: Ugur Sahin maintains substantial indirect exposure of 39,218,111 Ordinary Shares through Medine GmbH, an entity of which he is the sole shareholder.
• Significance: Although the direct position was liquidated, the sold amount represents approximately 0.16% of his aggregate beneficial holdings (over 39.2 million shares), leaving his core economic interest in BioNTech virtually intact.

Rule 10b5-1 Plan

Per the filing remarks, the reported transactions were executed pursuant to a pre-scheduled Rule 10b5-1 trading plan established on June 3, 2026, mitigating concerns regarding opportunistic selling or non-public information misuse.